Optimization of the management of drepanocytosis patients treated with hydroxyurea: Interest of the pharmacological therapeutic follow-up
This study is about improving how we use a medicine called hydroxyurea for people with sickle cell disease. It aims to find the best way to give this medication so it's most effective and has the fewest side effects. Researchers will be looking at how well the medicine works to reduce common problems of sickle cell disease, like pain crises, and how long it takes for a patient to reach their best dose. They will also check for any side effects on the body, such as changes in blood, kidney, or liver function. The goal is to make sure patients get the right amount of medicine tailored just for them, helping them to live healthier lives.
At a glance
What is this study about?
This study is called a 'Phase IV' trial. This means the medicine, hydroxyurea, is already approved and used by many people with sickle cell disease. The main goal isn't to see if the medicine works, but to find the very best way to manage patients who are taking it. Researchers want to understand how different doses affect people and how we can personalise treatment to each individual.
The study will look closely at how quickly patients reach the best dose of hydroxyurea for them. This best dose is called the 'LMA' (this term isn't explained further in the original text, but it likely refers to a target dose or level of medicine). They'll also monitor important things like how often patients experience pain crises, how many times they need to go to hospital, and if they need blood transfusions. These are all ways to see if the treatment is truly making a difference in patients' lives.
Researchers will also be checking for any side effects by doing regular blood tests to look at blood cells, kidney function, and liver function. They'll also try to understand how the body processes hydroxyurea differently in each person, looking at factors like age, weight, and kidney health. This detailed information will help doctors give more precise doses of hydroxyurea in the future, aiming for the best possible results for each patient with sickle cell disease.
Key takeaways
- This study focuses on improving how hydroxyurea is used for sickle cell disease.
- It aims to find the best, most personalised dose for each patient.
- Researchers will monitor how well the treatment reduces symptoms like pain crises.
- They will also check for any side effects on your body, like your blood, kidneys, and liver.
- The study is for adults (18 years and older) with sickle cell disease.
- Your participation will involve regular check-ups and blood tests.
Who may be eligible?
To be part of this study, you need to be at least 18 years old. There's no upper age limit, so adults of any age can potentially take part. The study is open to both men and women.
The main condition for joining is that you have sickle cell disease. More specific details about your health, current medications, and other medical conditions would be discussed with the study team to see if the study is right for you. It's important to know that before you can join, a doctor involved in the study will review your medical history to make sure it's safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have sickle cell disease?
- Are you open to regular check-ups and blood tests?
- Are you able to take the study medication as directed?
What does participation involve?
If you decide to take part, you'll be given hydroxyurea, which is a medicine already used for sickle cell disease. The study involves regular visits to the clinic where you'll have various assessments. This includes blood tests to check how the medicine is working and to monitor for any side effects on your blood, kidneys, and liver. They will also collect information on how you are feeling, such as how often you have pain crises or if you need to go to hospital.
The study will follow you to understand how long it takes to find your best dose of hydroxyurea and how well it helps you. The total duration of your participation isn't specified in detail but will involve ongoing monitoring and follow-up appointments. You will likely continue taking the prescribed medication and undergo periodic checks to track your progress and health.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is the main goal of this study?
The study aims to find the most effective way to give hydroxyurea to people with sickle cell disease, making their treatment work better and reducing side effects.
What medicine is being studied?
The study is looking at hydroxyurea, which is already a common treatment for sickle cell disease.
Who can join this study?
Adults aged 18 and over, both men and women, who have sickle cell disease.
Will I have more doctor appointments if I join?
Yes, you will have regular clinic visits for blood tests and other checks to monitor your health and the treatment.
Can I leave the study if I change my mind?
Yes, you can choose to leave the study at any time, and it won't affect your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.